A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502831-20-00

Acronym

TUD-BCMACA-078

Enrollment

Registered

2023-11-03

Start date

2024-02-15

Completion date

Unknown

Last updated

2023-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male and female adult patients with relapsed Multiple Myeloma or Diffuse large B-cell Non-Hodgkin’s Lymphoma shall be treated in the trial.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany

None listed

Source: EU CTIS · Data processed: Feb 4, 2026